Literature DB >> 9525747

Downregulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems.

N Rudra-Ganguly1, J Zheng, A T Hoang, P Roy-Burman.   

Abstract

Previously, we described cloning of three alternatively spliced mRNA forms of human FGF8, a, b, and e, of which the b form is the major expressed species in both normal and tumor prostatic epithelial cells. In this report, we describe construction and overexpression of sense and antisense sequences of either the full length FGF8b coding region (215-amino acids or 215aa), 103aa N-terminal part or a smaller N-terminal region (34aa), each including the 23aa putative signal peptide domain, via a retrovirus system. While the morphologic transforming activities of the sense 215aa and 103aa constructs were similar in NIH3T3 cells, 103aa displayed reduced soft agar clonogenic activity. The 34aa construct was practically inert in these assays, although its expression could mimic the ability of 215aa or 103aa in conferring cell growth under reduced serum condition. Overexpression of any of the three constructs in antisense orientation, however, was similarly effective in reversing the morphology and anchorage-independent growth property of FGF8b-transfected NIH3T3 cells. The expression of the antisense 215aa construct significantly reduced the growth rate of the human prostatic carcinoma DU145 cells and inhibited their soft agar clonogenic activity and in vivo tumorigenicity in nude mice. Taken together, these results identify N-terminal portions of FGF8 protein isoform for having the domains necessary for one or more of the biologic effects examined, and suggest that low levels of FGF8 expressed in prostatic epithelial cells may contribute significantly to their growth and tumorigenic properties.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525747     DOI: 10.1038/sj.onc.1201652

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma.

Authors:  A T Hoang; J Huang; N Rudra-Ganguly; J Zheng; W C Powell; S K Rabindran; C Wu; P Roy-Burman
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  A novel truncated env gene isolated from a feline leukemia virus-induced thymic lymphosarcoma.

Authors:  Y Shi; P Roy-Burman
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Suppression of prostate carcinoma cell invasion by expression of antisense L-plastin gene.

Authors:  J Zheng; N Rudra-Ganguly; W C Powell; P Roy-Burman
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

4.  Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts.

Authors:  Johanna Tuomela; Tove J Grönroos; Maija P Valta; Jouko Sandholm; Aleksi Schrey; Jani Seppänen; Päivi Marjamäki; Sarita Forsback; Ilpo Kinnunen; Olof Solin; Heikki Minn; Pirkko L Härkönen
Journal:  BMC Cancer       Date:  2010-10-30       Impact factor: 4.430

5.  Distribution and localization of fibroblast growth factor-8 in rat brain and nerve cells during neural stem/progenitor cell differentiation.

Authors:  Jiang Lu; Dongsheng Li; Kehuan Lu
Journal:  Neural Regen Res       Date:  2012-07-05       Impact factor: 5.135

6.  FGF8 isoform b expression in human prostate cancer.

Authors:  V J Gnanapragasam; M C Robinson; C Marsh; C N Robson; F C Hamdy; H Y Leung
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

7.  A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers.

Authors:  Arianna Giacomini; Sara Matarazzo; Katiuscia Pagano; Laura Ragona; Sara Rezzola; Michela Corsini; Emanuela Di Salle; Marco Presta; Roberto Ronca
Journal:  Oncotarget       Date:  2015-05-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.